Articles from Syntis Bio
Syntis Bio Reports Late-Breaking SYNTIETY-1 Data at ObesityWeek® 2026 Demonstrating Daily Oral SYNT-101 Mimics Gastric Bypass Hormone Response with Placebo-Like Tolerability
Syntis Bio, Inc., a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, in two posters, including a late-breaking presentation, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-driven gut-hormone response of gastric bypass surgery, produced placebo-adjusted weight loss over 28 days, and was well tolerated, with gastrointestinal (GI) adverse events comparable to placebo and no discontinuations.
By Syntis Bio · Via Business Wire · November 16, 2026
Syntis Bio Reports Phase 1/1b Results Demonstrating Weight-Loss and Satiety Hormone Modulation with Oral SYNT-101 in Patients with Obesity
Syntis Bio, Inc., a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced results from its 28-day multiple ascending dose (MAD) portion of its Phase 1/1b SYNTIETY-1 clinical trial evaluating SYNT-101 as a potential treatment of obesity.
By Syntis Bio · Via Business Wire · September 15, 2026
Syntis Bio Releases New Data Supporting Potential of SYNT-101 as a Once-Daily Oral Treatment for Obesity at European Congress on Obesity and Weight Management
Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, today announced positive preclinical and first-in-human data for its lead candidate, SYNT-101, an investigational once-daily oral treatment for obesity. The data are being presented today during two scientific sessions at the European Congress on Obesity and Weight Management (Obesity 2025) in Barcelona.
By Syntis Bio · Via Business Wire · April 10, 2025